Global Life Sciences M&A Outlook
$350.00
Global Life Sciences M&A Outlook report typically includes an overview of current merger and acquisition trends, highlights major deals and their implications for the market, assesses regional analysis, analyzes the competitive landscape, and identifies key players driving consolidation.
It also explores startup scenario, therapeutic focus, & emerging sectors within life sciences, such as biotechnology and pharmaceutical, while providing trends on last 5-year M&A activity based on market conditions, economic factors, and strategic interests of companies in the sector.
| 1.0 | Global Life Sciences M&A Landscape | 2023 |
|---|---|
| 1.1 | Life Sciences | Global M&A Outlook |
| 1.2 | Global Life Sciences M&A Activity 2023 | By Region |
| 1.3 | Life Sciences M&A deals announced since Jan 2018 to 2023 |
| 1.4 | M&A Deals Volume | By Sector & Year |
| 1.5 | Life Sciences acquisitions | Therapeutic Focus areas |
| 1.6 | M&A Deals Volume | By Sector | 2023 |
| 1.7 | Top Life Sciences M&A Deals | 2023 |
| 2.0 | Life Sciences M&A Regional Highlights |
| 2.1 | Global Life Sciences M&A Activity | YoY by Region |
| 2.2 | Life Sciences M&A deals announced since January 2018 |
| 2.3 | Life Sciences M&A Deals | By Region | 2018-2022 |
| 2.4 | Americas | M&A Activity by Year |
| 2.5 | Europe | M&A Activity by Year |
| 2.6 | APAC | M&A Activity by Year |
| 2.7 | Top Announced Deals of 2022 | By Region |
| 3.0 | Life Sciences M&A | Sector Segmentation |
| 3.1 | M&A Deals Volume | By Sector |
| 3.2 | M&A Deals Volume | By Sector & Year |
| 3.3 | Life Sciences M&A Deals | Biopharmaceutical |
| 3.4 | Life Sciences M&A Deals | Pharmaceutical |
| 3.5 | Life Sciences M&A deals | Trend 2018-22 (deal value > $1 billion) |
| 4.0 | Life Sciences M&A | Therapeutic Focus |
| 4.1 | Life Sciences acquisitions | Therapeutic Focus areas |
| 4.2 | Life Sciences acquisitions | Deals Value paid & Therapeutic category |
| 4.3 | Life Sciences acquisitions | Oncology deals |
| 4.4 | Life Sciences acquisitions | Immunology deals |
| 4.5 | Life Sciences acquisitions | Rare Disease deals |
| 4.6 | Trend 2018-22 with deals > $1 B | basis therapeutic focus |
| 4.7 | Top Players deals during 2018-22 | basis Therapeutic focus |
| 5.0 | Life Sciences M&A | Startup Scenario |
| 5.1 | Global LS M&A | Classification based on Company Type |
| 5.2 | Global LS M&A | Classification of Transactions (deals) |
| 5.3 | M&A | Startup & Young growth | Acquired Period & Therapeutic Focus |
| 5.4 | M&A | Startup & Young growth companies | Rare Disease |
| 5.5 | M&A | Startup & Young growing companies | Oncology |
| 5.6 | M&A | Startup & Young growing companies | Immunology |
| 5.7 | M&A | Startup & Young growth companies | Neurology |
| 6.0 | Case studies |
| 6.1 | Case Study | Pfizer acquires Seagen |
| 6.2 | Case Study | Merck acquiring Prometheus |
| 7.0 | Key Takeaways |
| 7.1 | Forward Looking Statement |
